The immunotherapeutic response in a cohort of PRJEB23709, the response group proved the higher LAMP3 expression level in LAMP3 with anti‐PD‐1 monotherapy and anti‐PD‐1/anti‐CTLA‐4 combined therapy in melanoma (p < 0.05) (Figure 6D). Here, CTLA4 is linked to melanoma.